ArticleInfectious diseases and therapy2024
Clinical Characteristics of Lung Consolidation with Mycoplasma pneumoniae Pneumonia and Risk Factors for Mycoplasma pneumoniae Necrotizing Pneumonia in Children.
Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 39 citations in OpenAlex.
- Assessment of predictive efficacy for prognosis of pediatric severeTranslational pediatrics · 2026Article
- Safety and long-term outcomes of surgical intervention in pediatrics with necrotizing pneumonia: a retrospective cohort study.European journal of pediatrics · 2026Article
- Association between normalizedTranslational pediatrics · 2026Article
- Independent risk factors and predictive model for high hospitalization costs in children with Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Blood-based inflammatory parameters and machine learning models for mortality prediction in critically ill pediatric pneumonia: a retrospective cohort study.Translational pediatrics · 2026Article
- Clinical analysis of Mycoplasma pneumoniae necrotizing pneumonia in children.BMC infectious diseases · 2026Article
- Analysis of the interventional effects of ambroxol hydrochloride and ontelukast sodium combined with azithromycin on immune function and C-reactive protein serum expression in children with severe Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Clinical correlation of A2063G gene mutation in mycoplasma pneumoniae pneumonia in children: a retrospective analysis.Frontiers in pediatrics · 2026Article
- Explainable machine learning for diagnosing severeFrontiers in pediatrics · 2026Article
- Development of a nomogram to predict acute liver injury in children withFrontiers in pediatrics · 2026Article
- Non-linear associations between inflammatory biomarkers andFrontiers in pediatrics · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Dynamic multiplex cytokine profiling to identify risk factors for Lung Consolidation and Necrotizing Transformation in Children withMediterranean journal of hematology and infectious diseases · 2026Article
- Designing a broad-spectrum multi-epitope vaccine against influenza A andFrontiers in public health · 2026Article
- Exploring Clinical Characteristics and Risk Factors ofJournal of inflammation research · 2026Article
- Nomogram to predict severeFrontiers in pediatrics · 2026Article
- Clinical Prediction of Necrotizing Pneumonia in Children With Mycoplasma pneumoniae: A Model Based on Early Response to Therapy.Canadian respiratory journal · 2026Article
- Pulmonary lesion volume ratio and laboratory parameters as risk factors for plastic bronchitis in pediatric refractory Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2025Article
- Differences in immune function and cytokine levels among children in different age groups with severe community-acquired pneumonia.Scientific reports · 2025Article
- A machine learning-based predictive model for multilobar pulmonary consolidation induced by macrolide-resistantMicrobiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMycoplasma pneumoniae necrotizing pneumonia (MPNP) is an uncommon but increasingly recognized severe complication of pneumonia, and the delayed diagnosis and treatment are prone to pulmonary sequelae. The aim of this study is to explore independent risk factors for MPNP in children with lung consolidation.
methodsA retrospective observational study was conducted on 118 children with MPNP (MPNP group) and 184 children with lung consolidation of Mycoplasma pneumoniae pneumonia (MPP) (control group) admitted to Children's Hospital Affiliated to Zhengzhou University from June 2018 to August 2023. Clinical manifestations and laboratory data were analyzed and the independent risk factors for MPNP in children were analyzed by multivariate logistic regression.
resultsThe age of onset, hospitalization days, fever days, proportion of dyspnea, chest pain, complications, and need for fiberoptic bronchoscopic alveolar lavage (FBAL) were higher than those in the control group, and the difference was statistically significant (P < 0.05). The levels of white blood cells (WBC), platelets, neutrophil percentage (N%), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), fibrinogen (Fbg), D-dimer (D-D), erythrocyte sedimentation rate (ESR), alanine transaminase (ALT), γ-glutamyl transpeptidase (γ-GGT), globulin, lactate dehydrogenase (LDH), α-hydroxybutyrate dehydrogenase (α-HBDH), urea, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), complement component 3, antistreptolysin O (ASO), serum ferritin, and interleukin-6 (IL-6) in the MPNP group were higher than those in the control group. Red blood cell (RBC), lymphocyte percentage (L%), activated partial thromboplastin time (APTT), alkaline phosphatase (ALP), total protein, albumin, albumin-to-globulin ratio (AGR), creatine kinase (CK), uric acid, natrium, chlorine, calcium, and complement C4 in the MPNP group were lower than those in the control group, and the difference was statistically significant (P < 0.05). The results of multivariate logistic regression analysis showed that age ≥ 83.50 months, fever days ≥ 10.50, ALT ≥ 15.25 U/l, IgM ≥ 1.46 g/l, complement C3 ≥ 1.47 g/l, Fbg ≥ 3.93 g/l, dyspnea and needing FBAL were independent risk factors for MPNP in children.
conclusionsAge, fever days, ALT, IgM, complement C3, Fbg, dyspnea, and needing FBAL were independent risk factors for MPNP in children. For children suspected of MPNP, pediatricians should pay close attention to the above indicators, strive for early diagnosis and treatment, and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.